A.P. Pharma Inc. (APPA)

13.07
0.06 0.46
NASDAQ : Health Care
Prev Close 13.01
Open 13.07
Day Low/High 12.59 / 13.44
52 Wk Low/High 6.40 / 15.82
Volume 170.20K
Avg Volume 655.70K
Exchange NASDAQ
Shares Outstanding 313.62M
Market Cap 138.09M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

A.P. Pharma Announces Pipeline Expansion

A.P. Pharma Announces Pipeline Expansion

A.P.

Grading the Twitterverse's 2013 Biotech Stock Picks

Grading the Twitterverse's 2013 Biotech Stock Picks

Some of your predictions were spot on, others not so much.

Leaders of <I>TheStreet's</I> Drug Approval Contest

Leaders of TheStreet's Drug Approval Contest

This group of contestants have nearly perfect records picking FDA and European drug approvals.

The Next Big Thing In Biotech: Decision Week

The Next Big Thing In Biotech: Decision Week

Ziopharm, AP Pharma and Biogen Idec will headline a very big week of approval decisions, Adam Feuerstein, Sr. Columnist at TheStreet, tells Gregg Greenberg.

Best And Worst FDA Drug Approval Stocks of 2013

Best And Worst FDA Drug Approval Stocks of 2013

Contestants in TheStreet's FDA Drug Approval Contest think well of Sarepta, Navidea and Biogen, less so about Arena, Aveo and Delcath.

Play TheStreet's FDA Drug Approval Contest

Play TheStreet's FDA Drug Approval Contest

Who will be the premier prognosticator of FDA drug approvals in 2013?

Biotech Stock Mailbag: Celsion, Navidea, AP Pharma, Sarepta

Biotech Stock Mailbag: Celsion, Navidea, AP Pharma, Sarepta

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies

A.P. Pharma Run-Up Trade Into FDA Approval Decision

A.P. Pharma Run-Up Trade Into FDA Approval Decision

Look at A.P. Pharma as a trade, not as a long-term investment, says trader Mark Messier.

AP Pharma, Delcath Systems: FDA 'Acceptance' Run-Up Trades

AP Pharma, Delcath Systems: FDA 'Acceptance' Run-Up Trades

The biotech bull market has created a new category of swing trade catalysts.